Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Fiche publication
Date publication
février 2017
Journal
The Lancet. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KLEINCLAUSS François
Tous les auteurs :
Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M,
Lien Pubmed
Résumé
Vascular-targeted photodynamic therapy, a novel tissue-preserving treatment for low-risk prostate cancer, has shown favourable safety and efficacy results in single-arm phase 1 and 2 studies. We compared this treatment with the standard of care, active surveillance, in men with low-risk prostate cancer in a phase 3 trial.
Mots clés
Adult, Aged, Aged, 80 and over, Bacteriochlorophylls, therapeutic use, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Photochemotherapy, Photosensitizing Agents, therapeutic use, Population Surveillance, Prognosis, Prostatic Neoplasms, drug therapy, Risk Assessment, Survival Rate
Référence
Lancet Oncol.. 2017 Feb;18(2):181-191